MYCN and neuroblastoma: The efforts associated with our approach are justified to enable sensitive detection of TERT rearrangements in this molecular high-risk subgroup of neuroblastoma, which does not overlap with cases harboring MYCN amplifications and includes both high-risk and very high–risk disease (2).